Skip to main content
SpringerLink
Log in

Adjuvant therapy cost effective for postmenopausal women with low-risk breast duct carcinoma?

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Ward MC, et al. Cost-Effectiveness Analysis of No Adjuvant Therapy Versus Partial Breast Irradiation Alone Versus Combined Treatment for Treatment of Low-Risk DCIS: A Microsimulation. JCO Oncology Practice : OP2000992, 10 May 2021

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adjuvant therapy cost effective for postmenopausal women with low-risk breast duct carcinoma?. PharmacoEcon Outcomes News 879, 1 (2021). https://doi.org/10.1007/s40274-021-7724-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-7724-x

Search

Navigation